Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis
Allergy2023Vol. 79(5), pp. 1258–1270
Citations Over TimeTop 10% of 2023 papers
Emma Guttman‐Yassky, Paola Facheris, Pedro Jesús Gómez‐Arias, Ester Del Duca, Joel Corrêa da Rosa, Stephan Weidinger, Robert Bissonnette, April W. Armstrong, Julien Sénéschal, Kilian Eyerich, Yeriel Estrada, Swaroop Bose, Dan Xu, Allshine Chen, Svitlana Tatulych, Erman Güler, Gary Chan, Karen Page, Urs Kerkmann
Abstract
Alongside improvements in clinical signs and symptoms of AD, 12 weeks of abrocitinib treatment resulted in downregulation of genes associated with inflammation, epidermal hyperplasia, and Th2 and Th22 immune responses in the skin of patients with moderate-to-severe AD.
Related Papers
- → IL‐31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis(2012)160 cited
- → Scoring atopic dermatitis and six sign atopic dermatitis: Comparison of prognostic and predictive value in atopic dermatitis(2013)5 cited
- → Assessment of the severity of atopic dermatitis — SCORAD and EASI(2022)3 cited
- → Serum OX40 ligand: a potential marker of atopic dermatitis disease severity in children(2009)2 cited
- Can the blood tryptase be an indicator of the severity of atopic dermatitis?(2020)